Biochimica et biophysica acta. Reviews on cancer最新文献_第5页

Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets 纤维化驱动的肝癌发生、转移和免疫逃避：机制和治疗靶点。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-18 DOI: 10.1016/j.bbcan.2025.189517

Zilong Zhang, Xiaoping Chen, Bixiang Zhang, Wanguang Zhang, Ze-yang Ding, on behalf of the Expert Group on Portal Hypertension of the Chinese College of Surgeons (CCS), Chinese Medical Doctor Association (CMDA)

{"title":"Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets","authors":"Zilong Zhang, Xiaoping Chen, Bixiang Zhang, Wanguang Zhang, Ze-yang Ding, on behalf of the Expert Group on Portal Hypertension of the Chinese College of Surgeons (CCS), Chinese Medical Doctor Association (CMDA)","doi":"10.1016/j.bbcan.2025.189517","DOIUrl":"10.1016/j.bbcan.2025.189517","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) arising on a background of fibrosis has fundamental mechanistic and clinical differences compared to HCC that arises in a non-fibrotic liver. The fibrotic microenvironment is characterized by extracellular matrix (ECM) remodeling, dynamic interactions with immune and stromal cells, and activation of hepatic stellate cells (HSCs) and cancer-associated fibroblasts (CAFs). Recent multi-omics analyses have demonstrated that these fibrotic niches dynamically promote hepatocarcinogenesis, metastasis and immune evasion. Several therapeutic strategies targeting fibrosis have improved HCC outcomes in clinical trials. These advances have facilitated an understanding of the complex mechanisms underlying fibrosis-driven HCC and are helping to optimize therapeutic prescriptions. This review synthesizes recent advances in understanding the role of fibrosis in hepatocarcinogenesis, aggressiveness, and metastasis; decodes how stromal-immune crosstalk defines immune escape through the fibrosis-driven ‘3C’ immune evasion framework; and links mechanistic insights into fibrosis-driven HCC with emerging theranostic strategies. We emphasize that targeting fibrosis-driven oncogenic mechanisms may enhance the therapeutic efficacy in HCC, thus providing a scientific foundation for rationalizing this approach as a viable strategy against both liver fibrosis and HCC.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189517"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MXene-based functional nanodrugs towards anticancer strategy and augmented sonodynamic therapy 基于mxene的功能纳米药物抗癌策略和增强声动力治疗

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2026-01-08 DOI: 10.1016/j.bbcan.2026.189531

Xueyan Wang , Jialu Li , Ru Li, Zonghua Wang, Zhanfeng Li

{"title":"MXene-based functional nanodrugs towards anticancer strategy and augmented sonodynamic therapy","authors":"Xueyan Wang , Jialu Li , Ru Li, Zonghua Wang, Zhanfeng Li","doi":"10.1016/j.bbcan.2026.189531","DOIUrl":"10.1016/j.bbcan.2026.189531","url":null,"abstract":"<div><div>MXene-based functional nanodrugs have stood out in the biomedical field owing to the attractive properties (e.g., excellent conductivity, high electromagnetic wave absorption capacity, rich surface functional groups, and easy functionalization), while sonodynamic therapy (SDT) has demonstrated excellent therapeutic efficacy because of its fast, noninvasive and deep-penetration advantages. Therefore, this review aims to summarize their cooperation in the improvements of anticancer activity. In the review, the progress of MXene-based functional nanodrugs is overviewed in the cancer treatment, where the single therapy and combinatorial therapy are described systematically. The development of MXenes as emerging sonosensitizers is narrated clearly during SDT and theranostics, focusing on various unique designs to improve the therapeutic efficacy. Moreover, we provide an in-depth analysis toward the MXene-harmonized multimodal SDT platforms, at length discussing a series of successes in the cancer treatments. Significantly, the challenges about the cooperation services of MXenes and SDT are also proposed, emphasizing more theoretical/technical innovations in the clinical antitumor applications.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189531"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel insights in the diagnosis and treatment of non-small cell lung cancer: Post-translational modification of proteins 在非小细胞肺癌的诊断和治疗的新见解：蛋白质的翻译后修饰。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-05 DOI: 10.1016/j.bbcan.2025.189507

Yuting Sun , Weijia Kong , Xiaoyu Zhu , Xuelei Chu, Xinmiao Wang, Guanghui Zhu, Xue He, Jie Li

{"title":"Novel insights in the diagnosis and treatment of non-small cell lung cancer: Post-translational modification of proteins","authors":"Yuting Sun , Weijia Kong , Xiaoyu Zhu , Xuelei Chu, Xinmiao Wang, Guanghui Zhu, Xue He, Jie Li","doi":"10.1016/j.bbcan.2025.189507","DOIUrl":"10.1016/j.bbcan.2025.189507","url":null,"abstract":"<div><div>Non-small cell lung cancer (NSCLC) is associated with a high incidence and mortality rate, imposing a significant economic burden worldwide. The development of standardized diagnostic and targeted therapeutic approaches is essential. Protein post-translational modifications (PTMs) play a critical role in regulating biological functions during both physiological and pathological states, as they reversibly and dynamically adjust protein activity in response to changes in internal and external conditions. Various types of PTMs, including ubiquitination, phosphorylation, glycosylation, Small Ubiquitin-like Modifier (SUMO)ylation, acetylation, palmitoylation, and lactylation, have been shown to correlate significantly with the onset, progression, metastasis, treatment, and drug resistance of NSCLC. These modifications are involved in the initiation and progression of NSCLC and are linked to patient survival outcomes. Additionally, different therapeutic modalities, such as chemotherapy, radiation therapy, and immunotherapy, can influence treatment efficacy by altering PTMs. However, the challenge of drug resistance significantly undermines therapeutic effectiveness and patient outcomes. This review emphasizes the importance of PTMs in drug resistance and highlights their potential to inform more precise treatment strategies for NSCLC, ultimately contributing to a reduction in disability-adjusted life years, which is of considerable practical importance.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189507"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145703231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistance 癌症中线粒体动力学失调：解锁对抗耐药性的新策略。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-06 DOI: 10.1016/j.bbcan.2025.189510

Teresa Rossi , Roberta Torcasio , Ludovica Ganino , Ilenia Valentino , Christian Boni , Massimo Gentile , Antonino Neri , Nicola Amodio , Mariaelena Pistoni

{"title":"Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistance","authors":"Teresa Rossi , Roberta Torcasio , Ludovica Ganino , Ilenia Valentino , Christian Boni , Massimo Gentile , Antonino Neri , Nicola Amodio , Mariaelena Pistoni","doi":"10.1016/j.bbcan.2025.189510","DOIUrl":"10.1016/j.bbcan.2025.189510","url":null,"abstract":"<div><div>Mitochondria continuously alternate between fragmented and fused states, a process known as mitochondrial dynamics, which plays a pivotal role in essential cellular functions, including metabolism, apoptosis, reactive oxygen species production, and signal transduction. Disruptions in this dynamic equilibrium, frequently observed in aggressive cancers, can promote malignant transformation and tumor progression. A growing body of evidence indicates that dysregulated mitochondrial dynamics contribute to resistance against both conventional and targeted anticancer therapies. In this review, we explore the regulatory mechanisms governing mitochondrial dynamics, with a focus on the genetic and epigenetic modulation of key drivers such as DRP1, MFN1/2 and OPA1. We also discuss how altered mitochondrial dynamics converge into diverse mechanisms of drug resistance in cancer. Overall, these insights underscore aberrant mitochondrial dynamics as a potential biomarker of therapeutic resistance, and position mitochondrial dynamics–related GTPases, particularly DRP1 and Mitofusins, as exploitable targets for novel treatments in advanced solid and hematologic malignancies.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189510"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting MAO offers a novel immunotherapeutic strategy for prostate cancer by modulating the “tumor-stroma-immune” interaction network 靶向MAO通过调节“肿瘤-基质-免疫”相互作用网络为前列腺癌提供了一种新的免疫治疗策略。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-04 DOI: 10.1016/j.bbcan.2025.189506

Yaohua Hu , Zhite Zhao , Yifan Ma , Xinglin He , Changhong Shi

{"title":"Targeting MAO offers a novel immunotherapeutic strategy for prostate cancer by modulating the “tumor-stroma-immune” interaction network","authors":"Yaohua Hu , Zhite Zhao , Yifan Ma , Xinglin He , Changhong Shi","doi":"10.1016/j.bbcan.2025.189506","DOIUrl":"10.1016/j.bbcan.2025.189506","url":null,"abstract":"<div><div>Prostate cancer (PCa) is a highly prevalent malignant tumor in men, often progressing to castration-resistant prostate cancer (CRPC) and metastasis or neuroendocrine differentiation, leading to treatment failure. Its high heterogeneity and immunosuppressive tumor microenvironment (TME) are major challenges in treatment, characterized by low immunogenicity and a complex “tumor-stroma-immune” interaction network. Monoamine oxidase (MAO), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines via MAOA and MAOB isoforms. Studies have shown that MAOA and MAOB exhibit differential expression patterns in cancer cells, stromal cells, and immune cells, and may function cooperatively to promote PCa progression. This review clarifies how MAO influence PCa progression by regulating the “tumor-stroma-immune” interaction network, elucidate the impact of MAO on CD8<sup>+</sup> T-cell infiltration and tumor-associated macrophages (TAMs) polarization in the TME, and proposes that precision targeting of MAO offers a stage- and cell-type-spanning strategy to surmount immunotherapy resistance in PCa. It provides a theoretical basis for developing intervention strategies based on MAO inhibitor to achieve effective immunotherapy for PCa.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189506"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

YY1 in four dimensions: From context-dependent transcription factor to spatiotemporal gene regulator 四个维度的YY1：从上下文依赖性转录因子到时空基因调控因子。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2026-01-03 DOI: 10.1016/j.bbcan.2025.189526

Silvia Vivarelli , Luca Falzone , Concettina Fenga , Massimo Libra

{"title":"YY1 in four dimensions: From context-dependent transcription factor to spatiotemporal gene regulator","authors":"Silvia Vivarelli , Luca Falzone , Concettina Fenga , Massimo Libra","doi":"10.1016/j.bbcan.2025.189526","DOIUrl":"10.1016/j.bbcan.2025.189526","url":null,"abstract":"<div><div>YY1 is a multifunctional transcription factor whose regulation spans transcriptional, post-transcriptional, and post-translational layers, conferring remarkable context-dependent plasticity. Several studies carried out in YY1-deficient mouse models highlight its essential roles in embryogenesis, organogenesis, and cellular homeostasis, while its deregulation in adulthood predisposes to multiple chronic diseases. In cancer, YY1 displays a bidirectional function, acting as either oncogene or tumor suppressor depending on cellular context and tumor type, and reshaping transcriptional and epigenetic networks. Emerging evidence further identifies YY1 as a clock-controlled gene and architectural regulator of circadian transcription, bridging together enhancer-promoter communication, chromatin state, and the temporal dimension of gene expression. In this context, its deregulation links circadian misalignment with oncogenic signaling, underscoring its key role as a diagnostic and prognostic biomarker, as well as a therapeutic target, thus highlighting its relevance in precision oncology.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189526"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

miRNA-HK2 networks in cancer metabolism: Mechanisms and dual-targeting therapeutic opportunities miRNA-HK2网络在癌症代谢中的作用：机制和双靶向治疗机会

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2026-01-06 DOI: 10.1016/j.bbcan.2026.189530

Xinyue Jiang , Xinnan Li , Leo Tsz On Lee , Kin Yip Tam

引用次数: 0

Role of N7-methylguanosine in gastrointestinal tumors: Molecular mechanisms and therapeutic targets n7 -甲基鸟苷在胃肠道肿瘤中的作用：分子机制和治疗靶点。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2026-02-01 Epub Date: 2025-12-07 DOI: 10.1016/j.bbcan.2025.189511

Jingyuan Li , Yangxian Xu , Lisheng Wang , Guang Ji , Yanqi Dang

{"title":"Role of N7-methylguanosine in gastrointestinal tumors: Molecular mechanisms and therapeutic targets","authors":"Jingyuan Li , Yangxian Xu , Lisheng Wang , Guang Ji , Yanqi Dang","doi":"10.1016/j.bbcan.2025.189511","DOIUrl":"10.1016/j.bbcan.2025.189511","url":null,"abstract":"<div><div>N7-methylguanosine (m<sup>7</sup>G), a widely prevalent post-transcriptional modification of RNA, exhibits significant regulatory changes across diverse RNA molecules, thereby affecting essential RNA metabolic processes. Aberrant levels of m<sup>7</sup>G modification have been increasingly linked to a broad spectrum of diseases, influencing oncogene expression and contributing to pathological mechanisms. The relationship between m<sup>7</sup>G modification and the initiation and progression of various tumor types is intricate and multifaceted. Moreover, current evidence suggests that m<sup>7</sup>G may play a role in regulating processes within immune cells, thereby implicating it in immune-related pathologies, including cancer. The targeted manipulation of m<sup>7</sup>G and its regulatory pathways holds significant promise for advancements in immunotherapy, potentially enhancing the modulation of immune responses and overcoming drug resistance. In gastrointestinal (GI) tumors, where immune evasion and therapy resistance are prominent challenges, understanding the role of m<sup>7</sup>G becomes particularly critical. This comprehensive review systematically examines the current body of research on m<sup>7</sup>G within the context of GI tumors, offering a detailed analysis of its dysregulated patterns in both malignant and immune cells. The molecular mechanisms underlying tumorigenesis mediated by m<sup>7</sup>G epigenetics are summarized, and therapeutic strategies aiming at targeting m<sup>7</sup>G modifications are discussed. Additionally, this review provides insights into potential future directions in the fields of diagnosis and prognosis.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1881 1","pages":"Article 189511"},"PeriodicalIF":9.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Steroidal derivatives in pancreatic cancer: Paving the way to new anticancer drugs 胰腺癌中的类固醇衍生物：为新的抗癌药物铺平道路。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-10-03 DOI: 10.1016/j.bbcan.2025.189468

Ana R. Gomes , Elisiário J. Tavares-da-Silva , Fernanda M.F. Roleira , Ana S. Pires

{"title":"Steroidal derivatives in pancreatic cancer: Paving the way to new anticancer drugs","authors":"Ana R. Gomes , Elisiário J. Tavares-da-Silva , Fernanda M.F. Roleira , Ana S. Pires","doi":"10.1016/j.bbcan.2025.189468","DOIUrl":"10.1016/j.bbcan.2025.189468","url":null,"abstract":"<div><div>Pancreatic cancer remains one of the most life-threatening cancers worldwide with limited therapeutic options and a poor prognosis. Despite the advances in treatment regimens, the death rate of pancreatic cancer patients continues to rise, justifying the need for novel therapeutic agents. Steroidal derivatives, with their unique modifiable framework, have emerged as a promising class of compounds in drug discovery, namely for the search for novel anticancer drugs.</div><div>A comprehensive review of studies on the anticancer activity of synthetic and natural steroidal derivatives for potential pancreatic cancer treatment was conducted, highlighting their structural versatility, mechanisms of action, and recent advances in their development. For this, an extensive literature search was conducted in two main databases – PubMed and Web of Science.</div><div>In the preclinical setting, the steroidal derivatives described throughout this review display their cytotoxicity by different mechanisms, which culminate in cell death mostly by apoptosis. Remarkably, many of the pathways affected by this class of compounds are considered key players in many of the <em>hallmarks of cancer</em>, which reinforces the importance of studying steroidal derivatives for the treatment of pancreatic cancer.</div><div>This review summarises the current state of research and underscores the potential of steroidal derivatives as a groundwork for novel therapeutic approaches in pancreatic cancer management, outlining future directions for their development as effective anticancer agents.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189468"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Animal models in preclinical evaluation of CAR-T cell therapy: Advantages and limitations CAR-T细胞治疗临床前评估的动物模型：优点和局限性。

IF 9.7 1区医学

Biochimica et biophysica acta. Reviews on cancer Pub Date : 2025-11-01 Epub Date: 2025-09-18 DOI: 10.1016/j.bbcan.2025.189455

Lasse von Bornemann Fløe , Maya Graham Pedersen , Bjarne K. Møller

{"title":"Animal models in preclinical evaluation of CAR-T cell therapy: Advantages and limitations","authors":"Lasse von Bornemann Fløe , Maya Graham Pedersen , Bjarne K. Møller","doi":"10.1016/j.bbcan.2025.189455","DOIUrl":"10.1016/j.bbcan.2025.189455","url":null,"abstract":"<div><div>Chimeric Antigen Receptor T (CAR-T) cell therapy is a promising new treatment category. Animal models have played a pivotal role in advancing CAR-T cell therapy. However, no animal model fully replicates human physiology, leading to unsuccessful translation from preclinical models to clinical trials. Understanding the advantages and limitations of various animal model choices requires insight into CAR-T cell mechanisms and their interactions across experimental contexts.</div><div>CAR-T cell immunobiology differs between animal models and humans. This disparity is reflected in the limited translational capacity of pharmacological parameters and the absence of key immunological interactions in animal models compared to those seen in human trials. Additionally, the antigen specificity of the CAR introduces translational limitations. Differences in antigen density and expression among different cellular populations across species are critical factors to consider when interpreting preclinical results. Xenoreactivity, stemming from the original T-cell receptor repertoire, also limits experimental duration and timing in mouse models.</div><div>Modeling human cancer in animal models requires many considerations. Cancer heterogeneity varies significantly between patient-derived xenografts and cell-line-based xenografts. Syngeneic models more accurately mimic interactions between CAR-T cells and other immune components, while xenograft models better reflect human tumor antigen expression. Beyond CAR-T-specific challenges, issues with standardization and replication in animal studies affect the reliability of the results. Furthermore, ethical guidelines should guide experimental planning to minimize animal use and prioritize humane treatment.</div><div>This review explores the strengths and limitations of animal models preclinical CAR-T cell therapy research, while offering critical considerations for interpreting results and designing experiments.</div></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1880 6","pages":"Article 189455"},"PeriodicalIF":9.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145103139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0